3 Stocks Pulling The Drugs Industry Downward

TheStreet highlights 3 stocks pushing the drugs industry lower today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 11 points (-0.1%) at 17,856 as of Thursday, Nov. 5, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,091 issues advancing vs. 1,846 declining with 161 unchanged.

The Drugs industry currently sits down 1.3% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include

bluebird bio

(

BLUE

), down 20.4%,

Valeant Pharmaceuticals International

(

VRX

), down 11.7%,

Celgene

(

CELG

), down 5.7%,

Gilead

(

GILD

), down 2.1% and

Vertex Pharmaceuticals

(

VRTX

), down 2.0%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Endo International

(

ENDP

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Endo International is down $7.10 (-11.7%) to $53.39 on heavy volume. Thus far, 6.7 million shares of Endo International exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $51.12-$60.42 after having opened the day at $58.60 as compared to the previous trading day's close of $60.49.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Endo International has a market cap of $12.8 billion and is part of the health care sector. Shares are down 16.1% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Endo International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Endo International

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Endo International Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Mylan

(

MYL

) is down $1.18 (-2.5%) to $45.40 on average volume. Thus far, 3.2 million shares of Mylan exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $44.64-$46.78 after having opened the day at $46.42 as compared to the previous trading day's close of $46.58.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $22.9 billion and is part of the health care sector. Shares are down 17.4% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Mylan a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Mylan

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Mylan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Merck

(

MRK

) is down $0.57 (-1.0%) to $54.96 on light volume. Thus far, 3.5 million shares of Merck exchanged hands as compared to its average daily volume of 13.7 million shares. The stock has ranged in price between $54.68-$55.68 after having opened the day at $55.46 as compared to the previous trading day's close of $55.53.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $155.2 billion and is part of the health care sector. Shares are down 2.2% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...